The role of microrna-221 and microrna-222 in Androgen- independent prostate cancer cell lines

Cancer Research

Volumn 69, Issue 8, 2009, Pages 3356-3363

  Sun, Tong ^a   Wang, Qianben ^a   Balk, Steven ^a   Brown, Myles ^b   Lee, Gwo Shu Mary ^a,c   Kantoff, Philip ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICRORNA; MICRORNA 221; MICRORNA 222; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL GROWTH; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANDROGENS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DIHYDROTESTOSTERONE; GENE EXPRESSION; HUMANS; MALE; MICRORNAS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 66049148777     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4112     Document Type: Article

References (35)

1. Huggins CB, Hodges CV. Studies on prostatic cancer. 1. The effect ot castration, of estrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
2. Feldman BJ, Feldman D. The development ot androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45. (Pubitemid 33741879)
3. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 2007; 8: 23-36. (Pubitemid 46012012)
4. Glinsky GV. An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway. Cell Cycle 2008; 7: 2570-83.
5. Kim DH, Sætrom P, Snøve O, Jr., Rossi JJ. MicroRNA- directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A 2008; 105: 16230-5.
6. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11: 441-50. (Pubitemid 44430905)
7. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007; 23: 175-205.
8. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006; 6: 857-66. (Pubitemid 44629897)
9. Esquela-Rerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006; 6: 259-69.
10. Yanaihara K, Caplen N, Bowman E. et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-98. (Pubitemid 43357945)
11. Roldo C, Missiaglia E, Hagan JP. et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol 2006; 24: 4677-84. (Pubitemid 46630931)
12. Lu J, Getz G, Miska EA. et. al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8. (Pubitemid 40839735)
13. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-5. (Pubitemid 47037493)
14. Culig Z, Hoffmann J, Erdel M. et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumor progression in a new model system. Br J. Cancer 1999; 81: 242-51. (Pubitemid 29423702)
15. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kipl in androgeninduced cell cycle arrest. Mol. Endocrinol. 1998; 12: 941-53. (Pubitemid 30660662)
16. Klein KA, Reiter RE, Redula J. et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997; 3: 402-8. (Pubitemid 27145681)
17. Horoszewicz JS, Leong SS, Chu TM. et al. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin. Biol. Res 1980; 37: 115-32.
18. Wang Q, Li W, Liu XS. et al. A hierarchical network of transcription factors governs androgen receptordependent prostate cancer growth. Mol. Cell 2007; 27: 380-92. (Pubitemid 47126935)
19. Wang Q, Carroll JS, Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol. Cell 2005; 19: 631-42. (Pubitemid 41219439)
20. Galardi S, Mercatelli N, Giorda E. et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kipl. J. Biol. Chem 2007; 282: 23716-24. (Pubitemid 47311902)
21. le Sage C, Nagel R, Egan DA. et al. Regulation of the p27 (Kipl) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007; 26: 3699-708. (Pubitemid 47236875)
22. Felli N, Fontana L, Pelosi E. et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A 2005; 102: 18081-6. (Pubitemid 41798505)
23. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 2008; 8: 253-67.
24. Medina R, Zaidi SK, Liu CG. et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res 2008; 68: 2773-80.
25. Shi XB, Xue L, Yang j. et al. An androgen-regulated miRNA suppresses Bakl expression and induces androgen-in dependent growth of prostate cancer cells. Proc Natl Acad Sci USA 2007; 104: 19983-8.
26. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008; 14: 417-24.
27. Volinia S, Calin GA, Liu CG. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U S A 2006; 103: 2257-61. (Pubitemid 43271657)
28. Reis EM, Nakaya HI, Louro R. et al. Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer. Oncogene 2004; 23: 6684-92. (Pubitemid 39265533)
29. He H, Jazdzewski K, Li W. et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl. Acad. Sci. USA 2005; 102: 19075-80. (Pubitemid 43049568)
30. Poliseno L, Tuceoli A, Mariani L. et al. MicroRNAs modulate the angiogenic properties of HUVESc. Blood 2006; 108: 3068-71.
31. le Sage C, Nagel R, Agami R. Diverse ways to control p27Kipl function: miRNAs come into play. Cell Cycle 2007; 6: 2742-9. (Pubitemid 350277164)
32. Fornari F, Gramantieri L, Ferracin M. et al. MiR-221 controls CDKKlC/p57 and CDKNlB/p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27: 5651-61.
33. Garofalo M, Quintavalle C, Di Leva G. et al. Micro- RNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008; 27: 3845-55.
34. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB. Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites. Science 2008; 320: 1643-7.
35. Kedde M, Strasser MJ, Boldajipour B. et al. RNA- binding protein Dndl inhibits microRNA access to target mRNA. Cell 2007; 131: 1273-86.